PBAC's latest decision on Oxycodone, tramadol, codeine, hydromorphone, morphine, tapentadol, buprenorphine, fentanyl: Recommended with restriction (2019). Considered for Short-term relief of acute severe pain unresponsive to non-opioid analgesics; management of chronic severe pain in cancer and palliative care settings.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients requiring short-term (2–3 days) relief of acute severe pain unresponsive to non-opioid analgesics; patients with chronic severe pain in cancer and palliative care settings where other treatment options have failed or are inappropriate.
Therapy area
Pain
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
Budget impact
$3M
ICER note
Not modelled; this is a regulatory/restrictions-change submission, not a new drug economic evaluation.